What's new

Changes detected each time the data is refreshed: new trials, status and phase changes, new papers and pipeline news. Each item links to its source. Newest first.

The first entries (seeded October 11, 2026) are items posted or updated in the 30 days before launch, not changes we observed live.

• October 10, 2026 New paper: Partial convergence of alternative polyadenylation changes across ALS-Associated RNA-Binding proteins.
  Ji C · Neuroscience · added to PubMed 2026-10-10
• October 9, 2026 New paper: Anti-HDGFL2 cryptic protein antibodies provide a sensitive readout of TDP-43 pathology and clinical disease features.
  Citrano KJ, Maheswari Jawahar VB, Reeves MM et al. · Cell reports. Medicine · added to PubMed 2026-10-09
• October 9, 2026 New paper: Lateral sclerosis in amyotrophic lateral sclerosis is an upper motor neuron distal axonopathy ("dying back"): a clinical-neuropathological study.
  Liu J, Ong K, Meng A et al. · Acta neuropathologica · added to PubMed 2026-10-09
• October 9, 2026 New paper: Multiple motor proteins regulate TDP-43 anterograde axonal transport.
  Feole M, Devoto VMP, Dragišić N et al. · Acta neuropathologica · added to PubMed 2026-10-09
• October 9, 2026 New paper: Targeting protein misfolding and aggregation in neurodegenerative diseases: challenges for the identification and validation of targets for small molecules.
  Choudhury A, Prabha S, Saeed MU et al. · Expert opinion on therapeutic targets · added to PubMed 2026-10-09
• October 6, 2026 New paper: SOD1 co-pathologies in the brain: insights from neuropathological evidence and implications.
  de Azevedo EM, Bernardo VS, Lima MMS et al. · Acta neuropathologica · added to PubMed 2026-10-06
• October 5, 2026 New paper: TDP-43 and ALS - what's wrong with my membranes?
  Dahlhaus R, Yalcin I, Tischer J et al. · Neurobiology of disease · added to PubMed 2026-10-05
• September 29, 2026 Pipeline update: VTx-002
  VTx-002 (VectorY Therapeutics): VectorY expanded the PIONEER-ALS Phase 1/2 trial from 12 to 36 participants.
• September 25, 2026 New paper: Integrative synaptosome multi-omics reveals disrupted synapse organization and localized cryptic transcripts in C9ORF72-frontotemporal dementia.
  Spillman AM, Alsop EB, Gittings LM et al. · Acta neuropathologica · added to PubMed 2026-09-25
• September 22, 2026 Trial record updated: A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
  Eli Lilly and Company · Recruiting. The ClinicalTrials.gov record was updated (the API doesn't say what changed).
• September 18, 2026 New paper: Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43(Q331K) mice.
  Viteri JA, Kerr NR, Brennan CD et al. · Neurobiology of disease · added to PubMed 2026-09-18
• September 17, 2026 Trial record updated: Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
  National Institute of Neurological Disorders and Stroke (NINDS) · Recruiting. The ClinicalTrials.gov record was updated (the API doesn't say what changed).
• September 15, 2026 New paper: Peripheral TDP-43 pathology in amyotrophic lateral sclerosis: toward a systemic proteinopathy.
  Codron P, Miranda M, Garnier M et al. · Acta neuropathologica · added to PubMed 2026-09-15
• September 11, 2026 New paper: Selective neuroprotection in the ALS-FTD spectrum: Mechanisms of neuronal resilience and translational perspectives.
  Inoue Y, Tanaka M, Oguchi T et al. · Brain research bulletin · added to PubMed 2026-09-11